Oct 25, 2017 | By Tess
German chemicals company BASF has signed an agreement with French biotech firm Poietis to continue developing services and products in the 3D bioprinting field.
The two companies, which have been collaborating for the past two years on cosmetics-related research, will be focusing their bioprinting efforts on the improvement of laser-assisted, bioprinted skin models which could have applications in the cosmetics sector.
According to the companies, their goal is to apply their joint 3D bioprinted skin project for the testing and evaluating of cosmetic ingredients and skin care products.
As Fabien Guillemot, founder and president of Poietis, explained: “Bioprinted 3D models are the method of choice for the predictive evaluation of ingredients as these models reproduce the cell environment in vitro by having mechanical and metabolic functionalities close to the vivo.”
The bioprinting technology used to create the artificial skin uses a laser-assisted method which builds up skin cells into different 3D structures. The innovative process has allowed BASF and Poietis to produce “fully printed skin equivalents” in just a couple of weeks, further opening the doors for ethical cosmetics testing as well as new and innovative skin care products.
Sebastien Cadau, head of tissue engineering development at BASF, added: “During our cooperation, we gained important insights like the parameters and kinetics of dermis maturation. A mature and thick dermis is an essential condition to obtain optimum results in epidermal printing.”
Through the first years of their collaboration, BASF and Poietis successfully developed a bioprinting technology that could automatically reproduce the former’s Mimeskin, which is apparently one of the “closest equivalents to the original physiological tissue of human skin.”
Poietis' laser-assisted 3D bioprinter
Now, through their renewed agreement, the two European companies will continue their efforts in the hopes of refining the technology as well as the skin models. Cadau explains that this will involve increasing the complexity of the skin cell structures and experimenting with new cell types.
“This agreement confirms a fruitful scientific collaboration and strengthens our partnership with the leading ingredients manufacturer for the personal care market,” added Bruno Brisson, co-founder and vice president of business development at Poietis. “This is a formal recognition of Poietis' unique technology and its valorization driven by new developments since the creation of the company.”
BASF’s ultimate goal is to leverage the skin 3D bioprinting technology to bring to market new active ingredients for the cosmetics industry. The company recently showcased the potential of the technology with the presentation of Dermagenist™, its first active ingredient tested and confirmed using the jointly developed laser-assisted bioprinted skin models.
Posted in 3D Printing Application
Maybe you also like:
- T-Bone Cape motion control board launches on Indiegogo
- New extruder could lower costs of 3D printing cellular structures for drug testing
- New Ninja Printer Plate for consumer 3D printing
- mUVe3D releases improved Marlin firmware for all 3D printers
- Zecotek plans HD 3D display for 3D printers
- Add a smart LCD controller to your Robo3D printer
- Maker Kase: a handy cabinet for 3D printers
- Heated bed for ABS printing with the Printrbot Simple XL
- Next gen all metal 3D printer extruder from Micron
- Pico all-metal hotend 100% funded in 48 hours, B3 announces Stretch Goal
- Create it REAL announces first 3D printing Real Time Processor
- A larger and more powerful 3D printer extruder on Kickstarter
Dear Tess, thank you very much for sharing information about our company but please update the logotype and the printer picture! http://poietis.com/en/media.php
3Ders.org provides the latest news about 3D printing technology and 3D printers. We are now seven years old and have around 1.5 million unique visitors per month.
